I. MODIFIED AGREEMENTS

Biotech Co.* (Country; Symbol)

Pharma Co. (Country)

Change from original agreement

Terms/Details (Date)

Adherex Technologies Inc. (AMEX:ADX)

GlaxoSmithKline plc (UK)

Adherex acquired all rights to the cancer agent eniluracil, which was the subject of a July 2005 option agreement

GSK had options to reacquire eniluracil at various points of development; Adherex paid $1M to purchase the remaining options (1/18)

Coley Pharmaceutical Group Inc. (COLY)

GlaxoSmithKline plc (UK)

They changed from exclusive to nonexclusive a deal to use Coley's VaxImmune vaccine adjuvant product in certain infectious disease vaccines

Coley got rights to enter other deals to use VaxImmune in infectious disease vaccines; its milestone and royalty potential with GSK was reduced; their deal in the area of cancer was not changed (12/8)

Cytokinetics Inc. (CYTK)

GlaxoSmithKline plc (UK)

Under an amended deal, Cytokinetics assumed responsibility for the continued development of ispinesib (SB-715992) and SB-743921

The kinesin spindle protein inhibitors are being developed for cancer indications; GSK retained an option to regain rights to the programs; if so, it would pay more than originally contemplated; if not, it would get royalties on any resulting sales (11/27)

GTC Biotherapeutics Inc. (GTCB)

LEO Pharma A/S (Denmark)

GTC transferred to LEO the market authorization of ATryn, a recombinant form of human antithrombin

The move followed European approval of the product, on which the companies already were partnered; it will help LEO prepare for commercial launch (1/3)

Nastech Pharmaceutical Co. Inc. (NSTK)

Procter & Gamble Pharmaceuticals Inc.

They amended deal covering development of the osteoporosis agent PTH1-34, a parathyroid hormone nasal spray

The $15M Nastech expected to receive in 2006 was deferred to a $5M payment upon initiation of an additional Phase II trial, and $10M upon initiation of Phase III (12/4)

Neose Technologies Inc. (NTEC)

BioGeneriX AG (Germany; unit of Ratiopharm Group)

BioGeneriX decided to proceed with development of GlycoPEG-GCSF under their existing collaboration

Separately, BioGeneriX declined to exercise its option to license Neose's GlycoPEGylation technology for use with an undisclosed protein (12/29)

NeuroSearch A/S (Denmark; CSE:NEUS)

GlaxoSmithKline plc (UK)

They restructured and expanded five-year deal from 2003 covering ion channel modulators for treating central nervous system diseases

NeuroSearch will assume greater development responsibilities and costs; also, the deal was expanded to include certain non-CNS indications; NeuorSearch remains entitled to significant milestone and royalty payments (11/15)

Oscient Pharmaceuticals Corp. (OSCI)

LG Life Sciences Ltd. (South Korea)

They added several countries in Europe to license deal covering sales of the antibiotic Factive

The license now includes all of Europe; also, they reduced the royalty rate payable to LG on sales; the goal is finding a commercialization partner in Europe (12/29)

XOMA Ltd. (XOMA)

Schering-Plough Corp.

Schering-Plough exercised its right to initiate additional discovery and development programs under their collaboration for therapeutic antibody products

XOMA has received up-front payments for each of the additional collaboration programs and will get research funding, milestone payments and royalties (1/17)

II. TERMINATED AGREEMENTS

DOV Pharmaceutical Inc. (PK:DOVP)

Merck & Co. Inc.

Deal covering development of DOV 21,947 and DOV 216,303 was terminated

DOV regained all rights to the compounds, which target central nervous system diseases; no payments were due upon the termination (12/7)

Epigenomics AG (Germany; FSE:ECX)

Roche Diagnostics (Switzerland)

Roche ended collaboration focused on development of a range of molecular diagnostic cancer products

The deal began in 2002; Epigenomics regained all rights to the programs (12/15)

4SC AG (Germany; FSE:VSC)

Schwarz Pharma AG (Germany)

Schwarz ended R&D efforts in a urology-focused deal they began in 2003

4SC regained all rights; Schwarz is eligible to receive a share of potential license earnings (12/12)

GTx Inc. (GTXI)

Ortho Biotech Products LP (subsidiary of Johnson & Johnson)

GTx reacquired all rights to andarine, a selective androgen receptor modulator, and all backup compounds

Termination of the March 2004 deal gave GTx full ownership of its SARM portfolio (12/8)

PDL BioPharma Inc. (PDLI)

Hoffmann-La Roche Inc.

Roche is ending deal to develop Zenapax (daclizumab) for use in organ transplantation

That follows Roche's earlier decision to end its involvement in Zenapax in treating asthma; PDL now hold all rights in those indications (11/21)

SemBioSys Genetics Inc. (Canada; TSX:SBS)

Lonza Inc.

They ended deal covering the manufacture and sale of SemBioSys' DermaSphere Oleosome technology

SemBioSys regained full rights in exchange for a one-time payment; it plans to continue supplying the product to the personal care market (12/22)

Notes:

^# The information in the chart does not cover agreements between biotech companies or agricultural agreements.

* Private companies are indicated with an asterisk.

Unless otherwise noted, stock symbols listed are on the Nasdaq market.

AMEX = American Stock Exchange; CSE = Copenhagen Stock Exchange; FSE = Frankfurt Stock Exchange; PK = Pink Sheets; TSX = Toronto Stock Exchange.